TY - JOUR
T1 - Invasive Infections Due to Candida krusei
T2 - Report of Ten Cases of Fungemia that Include Three Cases of Endophthalmitis
AU - McQuillen, Daniel P.
AU - Zingman, Barry S.
AU - Meunier, Françoise
AU - Levitz, Stuart M.
PY - 1992/2
Y1 - 1992/2
N2 - Candida krusei has become an increasingly important invasive pathogen, particularly in immunocompromised patients. Previous experimental and clinical experience suggest that C. krusei has a low propensity for hematogenously infecting the eye. We report 10 cases of fungemia due to C. krusei at our institutions, including three cases of endophthalmitis due to C. krusei. Fungemia was associated with nodular skin lesions in all seven patients with neutropenia and occurred despite administration of antifungal prophylaxis or empirical therapy. None of the patients apparently died as a direct result of C. krusei fungemia. Treatment with amphotericin B resulted in resolution of endophthalmitis, although one patient required vitrectomy. Early institution of aggressive therapy with amphotericin B may alter the course and improve the prognosis of C. krusei infection, particularly in immunocompromised patients.
AB - Candida krusei has become an increasingly important invasive pathogen, particularly in immunocompromised patients. Previous experimental and clinical experience suggest that C. krusei has a low propensity for hematogenously infecting the eye. We report 10 cases of fungemia due to C. krusei at our institutions, including three cases of endophthalmitis due to C. krusei. Fungemia was associated with nodular skin lesions in all seven patients with neutropenia and occurred despite administration of antifungal prophylaxis or empirical therapy. None of the patients apparently died as a direct result of C. krusei fungemia. Treatment with amphotericin B resulted in resolution of endophthalmitis, although one patient required vitrectomy. Early institution of aggressive therapy with amphotericin B may alter the course and improve the prognosis of C. krusei infection, particularly in immunocompromised patients.
UR - http://www.scopus.com/inward/record.url?scp=0026515793&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026515793&partnerID=8YFLogxK
U2 - 10.1093/clinids/14.2.472
DO - 10.1093/clinids/14.2.472
M3 - Article
C2 - 1554833
AN - SCOPUS:0026515793
VL - 14
SP - 472
EP - 478
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 2
ER -